Media coverage about Bioblast Pharma (NASDAQ:ORPN) has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bioblast Pharma earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.161951382193 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Separately, ValuEngine upgraded Bioblast Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.
Shares of Bioblast Pharma (ORPN) traded down $0.12 during mid-day trading on Wednesday, reaching $2.47. The company had a trading volume of 66,300 shares, compared to its average volume of 126,533. Bioblast Pharma has a 1-year low of $1.49 and a 1-year high of $7.75. The company has a market capitalization of $8.56, a PE ratio of -0.96 and a beta of -0.05.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Bioblast Pharma (ORPN) Stock Price” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.themarketsdaily.com/2018/01/10/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-bioblast-pharma-orpn-stock-price.html.
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.
Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with MarketBeat.com's FREE daily email newsletter.